---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Co-prescribed/Concomitant therapies. Topics: Background second-generation H1 antihistamine at a stable regimen in the phase 3 trials, Live vaccines excluded within 30 days before screening in the phase 3 trials; inactivated vaccines allowed, Phase 3b long-term extension observation group: standard of care with at least second-generation H1 antihistamines, Phase 2 background H1 antihistamine and live vaccine exclusion within 2 months, and 1 further topic. 5 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Background second-generation H1 antihistamine at a stable regimen in the phase 3 trials

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment”
> “CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:”
> “Must be on a stable regimen of second generation non-sedating H1-antihistamine for”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023); [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

> “Antihistamine refractory CSU, (1-4x approved dose) including patients with advanced therapy experienced/refractory CSU”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.2.12-2"></a>

### Live vaccines excluded within 30 days before screening in the phase 3 trials; inactivated vaccines allowed

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment”
> “Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.12-3"></a>

### Phase 3b long-term extension observation group: standard of care with at least second-generation H1 antihistamines

> “A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13”
> “Group 1 Observation Group”
> “Standard of care treatment (at least 2nd generation Type 1 antihistamines”
> “with or without other permitted background medications) for 52 weeks.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-2.1.2.12-4"></a>

### Phase 2 background H1 antihistamine and live vaccine exclusion within 2 months

> “A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Spontaneous Urticaria”
> “Diagnosis of CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:”
> “Vaccination of a live vaccine within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study). Inactivated vaccines are allowed such as seasonal influenza injection or COVID-19 vaccine.”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-2.1.2.12-5"></a>

### Phase 1b add-on to H1 antihistamine alone or with H2 antihistamine or leukotriene receptor antagonist, with rescue antihistamines

> “Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up”
> “over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion). Rescue treatments were allowed up to maximum allowable doses: diphenhydramine 100 mg 4× daily (QID), hydroxyzine 50 mg QID, or H2 antihistamine 4× the recommended dose.”
> “This study was limited by the small sample size and variation in drugs used for background urticaria treatment; however, patients had to be on a stable regimen prior to barzolvolimab administration.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
